Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preferred chemotherapy regimen during radiotherapy for esophageal cancer
IRCT20240701062297N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, fluorouracil, folinic acid, carboplatin, paclitaxel and 1 more in esophageal cancer, gastroesophageal junction adenocarcinoma and Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Tumor location according to EUS report, Pathological grade and 3 more. Started Sep 2024; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acidcarboplatinpaclitaxel
03
Conditions
esophageal cancergastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on IRCT20240701062297N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240701062297N1.